Group 1 - The three major indices experienced fluctuations and turned negative, with the pharmaceutical and biotechnology sectors declining. The medical device sector saw a slight drop, with the CSI Medical Devices and Services Index falling by 0.34%. Notable gainers included Yingke Medical, which rose over 3%, and Hualan Shares and Guanhao Biological, which also had significant increases [1] - The Medical Device ETF (159873) recorded a half-day trading volume of nearly 9 million yuan, leading among similar products, with a turnover rate exceeding 3%. Over the past 10 days, the ETF has seen a cumulative net inflow of 119 million yuan, bringing its latest scale to 236 million yuan, making it the largest in its category [1] - The Medical Device ETF closely tracks the CSI Medical Devices and Services Index, which selects listed companies corresponding to the healthcare theme from the CSI All Share Index to reflect the overall performance of these companies [1] Group 2 - The Innovation Drug ETF Tianhong (517380) has also seen continuous net inflows, accumulating 426 million yuan over the past 12 days. It is the only ETF in the market tracking the Hang Seng Hong Kong-Shenzhen Innovation Drug Selected 50 Index, covering the entire industry chain from preclinical research to commercialization [2] - According to industry insiders, multiple public fund institutions have applied for medical and healthcare-themed funds this year. It is anticipated that the pharmaceutical industry will gradually recover from its bottom by 2026, with overall revenue growth stabilizing. Key focus areas will include the innovative drug industry chain, CXO (Contract Research Organization) sector, and innovative medical consumables [2] - CITIC Securities highlighted the significance of innovation, noting that Chinese pharmaceuticals possess advantages in "innovation upgrades and supply chain resilience." By 2025, the upfront payments for overseas licensing of innovative drugs are expected to significantly exceed the total for the previous year, with medical devices also exploring international markets [2]

Investment Rating - The report maintains a positive investment rating for the pharmaceutical sector [6] Core Insights - The pharmaceutical sector experienced a week-on-week decline of 0.68%, underperforming compared to the ChiNext and CSI 300 indices, ranking 17th among all industries [2][36] - The report emphasizes the importance of innovation, international expansion, and overcoming challenges as key themes for investment in 2026, with a focus on BD 2.0, small nucleic acids, and supply chain opportunities [3][4] - The upcoming adjustment of the National Essential Drug List is seen as critical, aiming to address clinical needs that have evolved since the last update in 2018, particularly in pediatrics, oncology, and rare diseases [5][14] Summary by Sections National Essential Drug List Adjustment Analysis - The current drug list has not been updated since 2018, leading to a disconnect with clinical needs, necessitating a systematic adjustment [14] - The adjustment will focus on filling gaps in disease coverage, particularly in pediatrics, oncology, and rare diseases, while also solidifying the integration of collective procurement and national negotiation outcomes [18][19] - The report identifies potential beneficiaries in traditional Chinese medicine, particularly in areas with previously weak coverage [28] JP Morgan Conference Overview - The 44th JP Morgan Health Conference highlighted strategic developments from major global pharmaceutical companies, showcasing their core pipeline advancements and key clinical milestones for 2026 [33] - Companies like Pfizer, Merck, and Eli Lilly presented their focus on innovative treatments and upcoming clinical trials, indicating a robust pipeline for future growth [34][35] Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance in early 2026 has shown a 7.08% increase, outperforming both the CSI 300 and ChiNext indices [36] - The report notes a shift in market sentiment, with certain innovative sectors like AI healthcare and medical robotics showing strong performance, while traditional sectors faced adjustments [2][3]

数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本基金业绩 表现的保证。投资人购买基金，既可能按其持有份额分享基金投资所产生的收益，也可能承担基金投资 所带来的损失。投资人应当认真阅读《基金合同》《招募说明书》等基金法律文件，全面认识本基金的 风险收益特征和产品特性，并根据自身的投资目的、投资期限、投资经验、资产状况等判断基金是否和 投资人的风险承受能力相适应，理性判断市场，谨慎做出投资决策。本材料中相关信息来源于基金管理 人认为可靠的公开资料，相关观点、评估和预测仅反映当前的判 ...

Investment Rating - The report maintains a "Hold" rating for the pharmaceutical sector [6] Core Insights - The pharmaceutical sector experienced a week-on-week decline of 0.68%, underperforming both the ChiNext Index and the CSI 300 Index, ranking 17th among all industries [2][36] - The report emphasizes a positive outlook for innovation, international expansion, and turnaround opportunities in the pharmaceutical industry, with a focus on BD 2.0, small nucleic acids, and supply chain [3][4] Summary by Sections 1. National Essential Drug List Adjustment Analysis - The adjustment of the National Essential Drug List is urgent as the current version has not been updated since 2018, leading to a disconnect with current clinical needs [14] - The new adjustments will focus on three main areas: addressing gaps in disease coverage, solidifying the integration of centralized procurement and national negotiation results, and enhancing the evidence-based standards for traditional Chinese medicine [5][14] - Potential beneficiaries from the adjustments include companies like Panlong Pharmaceutical, Guizhou Sanli, and Yiling Pharmaceutical, particularly in pediatrics, orthopedics, and cardiovascular fields [5][28] 2. JP Morgan Conference Overview - The 44th JP Morgan Health Conference highlighted strategic developments from major global pharmaceutical companies, showcasing their core pipeline progress and key clinical milestones for 2026 [33] - Companies such as Pfizer, Merck, and Eli Lilly presented their focus on advancing clinical trials and launching new products in various therapeutic areas [34][35] 3. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance from January 12 to January 16 showed a decrease of 0.68%, with a total trading volume of 916.83 billion yuan, accounting for 5.35% of the total market [2][36] - The report notes that the sector has shown a year-to-date increase of 7.08%, outperforming both the CSI 300 and ChiNext indices [36]

Core Insights - The first A-share performance report for 2025 has been released by WoHua Medical, showing a revenue of 817 million yuan, a year-on-year increase of 6.96%, and a net profit of approximately 95.71 million yuan, up 162.9% [1] - The pharmaceutical industry is experiencing a recovery trend, with several companies exceeding profit growth expectations for 2025, including WuXi AppTec, WoHua Medical, Kangchen Pharmaceutical, and Baiaosaitu, all reporting net profit growth exceeding 100% [1] Company Performance - WoHua Medical's significant profit increase is attributed to 93 products being included in the national medical insurance directory and 43 in the national essential drug list, with core products showing stable sales [4] - WuXi AppTec is expected to achieve a revenue of approximately 45.46 billion yuan in 2025, a year-on-year increase of about 15.8%, and a net profit of about 19.15 billion yuan, up approximately 102.65% [3] - Kangchen Pharmaceutical anticipates a net profit between 145 million and 175 million yuan for 2025, representing a year-on-year increase of 243% to 315% [5] - Baiaosaitu expects a revenue of 1.35 billion yuan in 2025, a year-on-year increase of 37.75%, and a net profit of approximately 135 million yuan, up about 303.57% [6] Losses and Challenges - Some pharmaceutical companies, such as Zhifei Biological, are facing significant losses, with an expected loss of 10.698 billion to 13.726 billion yuan for 2025, marking the first annual loss since its listing in 2010 [8] - Lianhuan Pharmaceutical is also projected to report its first loss since 2003, with preliminary estimates indicating a negative net profit for 2025 [9] - Newway is expected to incur a net loss of 170 million to 255 million yuan in 2025, primarily due to increased R&D expenses and declining profits from its traditional caffeine business [10]

Core Insights - The U.S. biotech industry is increasingly dependent on China, which has become a critical player in drug development and innovation [4][5][18] - China's role has evolved from contract research and manufacturing to significant contributions in novel drug discovery and licensing [17][19] Industry Overview - Major biotech hubs in the U.S. include Boston, San Francisco, and San Diego, while China has developed significant life-science clusters in cities like Shanghai and Beijing [3] - Zhangjiang Science City in Shanghai hosts over 1,700 biomedical companies, including major global pharmaceutical firms [3] Financial Landscape - The average cost for a big pharma company to develop a drug in 2024 is $2.23 billion, while biotech startups require a median investment of $304.1 million to develop FDA-approved biologics [5][6] - U.S. biotech funding has declined, with only 8.3% of venture funding going to biotech in 2025, the lowest in over 20 years [6][7] Research and Development - China conducted nearly one-third of the world's clinical trials in 2024, benefiting from lower operational costs and a unified data system [13][15] - The National Medical Products Administration (NMPA) has significantly increased its capacity, clearing a backlog of drug applications much faster than the FDA [15] Licensing and Innovation - In 2024, the value of drugs licensed from China to the West reached $48 billion, a 15-fold increase since 2020, with Chinese firms accounting for nearly a third of large licensing deals [18][19] - The share of global licensing deals from Chinese companies increased from 5% in 2019 to 48% in 2025, while U.S. companies' share dropped from 55% to 29% [18] Regulatory Environment - The U.S. government has enacted the BIOSECURE Act, restricting federal agencies from purchasing biotech products from certain companies, signaling a shift in the regulatory landscape [21][24] - The Act reflects the growing perception of biotechnology as a matter of national security, potentially altering the dynamics of U.S.-China biotech relations [24]

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]

Core Viewpoint - The A-share listed companies are entering a concentrated disclosure period for their 2025 performance forecasts, with over 580 companies having disclosed their forecasts, and around 300 companies expecting a year-on-year increase in net profit [1] Group 1: Performance Forecasts - Among the companies with positive performance forecasts, 100 companies expect a net profit increase of over 100%, and 17 companies anticipate an increase of over 300% [1] - The electronics, semiconductor, new energy, and non-ferrous metals industries are showing particularly strong performance [1] Group 2: Notable Companies and Their Forecasts - Huisheng Biological is expected to have a net profit increase of 1265.93% to 1444.54%, with a forecasted net profit of 235 million to 271 million yuan, attributed to market expansion and price increases [2] - Zijin Mining, a leader in the non-ferrous metals sector, forecasts a net profit of 51 billion to 52 billion yuan, a year-on-year increase of 59% to 62%, driven by increased production and sales prices [3] - Shenghong Technology, a PCB leader, anticipates a net profit of 4.16 billion to 4.56 billion yuan, with a year-on-year growth of 260.35% to 295%, supported by advancements in AI computing and high-performance computing [4] Group 3: Industry Trends - The "hard technology" sector is experiencing enhanced profitability due to the growing global demand for AI infrastructure and computing power [3] - Companies like Bawei Storage expect a net profit increase of 427.19% to 520.22%, with improvements in sales revenue and gross margin anticipated from the second quarter of 2025 [3] - Other technology companies, including Changxin Bochuang and Ding Tai High-Tech, are also forecasting potential doubling or more in their performance [5]

Group 1 - The JPMorgan Healthcare Conference (JPM2026) commenced on January 12 in San Francisco, showcasing 24 Chinese innovative pharmaceutical companies through main stage presentations and Asia-Pacific sessions [1] - Notable companies such as BeiGene, Zai Lab, Ascentage Pharma, and Legend Biotech presented their latest research and commercialization achievements, alongside CXO companies like WuXi AppTec and WuXi Biologics [1] - The report titled "2026 Global M&A Annual Outlook" indicates that global M&A transaction volume surged to $5.1 trillion in 2025, with the healthcare sector leading with a 44% increase [1] Group 2 - Analysts predict that medium-sized transactions valued between $5 billion and $15 billion will remain active in 2026 [1] - The Hang Seng Biotechnology Index focuses on innovative drug "crown jewels," highlighting three main advantages: concentration of leading companies, scarcity of futures liquidity, and high elasticity & high Sharpe ratio [1] - Investors looking for convenient access to core leaders in innovative pharmaceuticals are encouraged to consider the Hang Seng Biotechnology ETF (520933) for streamlined investment [1]

Core Viewpoint - The report highlights the current premium rates of AH shares, with Northeast Electric, Zhejiang Shibao, and Junda Co. leading in premium rates, while CATL, Hengrui Medicine, and China Merchants Bank are at the bottom of the list [1][2]. Premium Rate Rankings - Northeast Electric (00042) has a premium rate of 815.25%, followed by Zhejiang Shibao (01057) at 378.67% and Junda Co. (02865) at 342.63% [2]. - The lowest premium rates are recorded for CATL (03750) at -13.79%, Hengrui Medicine (01276) at -2.52%, and China Merchants Bank (03968) at -2.22% [1][2]. Deviation Values - Junda Co. (02865) has the highest deviation value at 104.89%, followed by Goldwind Technology (02208) at 23.62% and Guanghetong (00638) at 20.17% [1][2]. - The lowest deviation values are for Northeast Electric (00042) at -35.64%, Chenming Paper (01812) at -16.87%, and China Life (02628) at -15.34% [1][4]. Additional Insights - The report includes a detailed table of the top ten and bottom ten AH stocks based on premium rates and deviation values, providing a comprehensive overview of the current market situation [2][3][4].